2019 Q1 Form 10-Q Financial Statement
#000156459019018007 Filed on May 09, 2019
Income Statement
| Concept | 2019 Q1 | 2018 Q1 |
|---|---|---|
| Revenue | $37.10M | $0.00 |
| YoY Change | -100.0% | |
| Cost Of Revenue | $2.225M | $0.00 |
| YoY Change | ||
| Gross Profit | $34.87M | $0.00 |
| YoY Change | ||
| Gross Profit Margin | 94.0% | |
| Selling, General & Admin | $32.68M | $16.58M |
| YoY Change | 97.16% | -11.82% |
| % of Gross Profit | 93.72% | |
| Research & Development | $18.79M | $25.46M |
| YoY Change | -26.19% | -52.66% |
| % of Gross Profit | 53.88% | |
| Depreciation & Amortization | $700.0K | $900.0K |
| YoY Change | -22.22% | 0.0% |
| % of Gross Profit | 2.01% | |
| Operating Expenses | $53.70M | $42.03M |
| YoY Change | 27.75% | -42.09% |
| Operating Profit | -$16.60M | -$42.03M |
| YoY Change | -60.51% | -41.96% |
| Interest Expense | $4.216M | $2.408M |
| YoY Change | 75.08% | 1.35% |
| % of Operating Profit | ||
| Other Income/Expense, Net | $811.0K | $138.0K |
| YoY Change | 487.68% | -575.86% |
| Pretax Income | -$20.00M | -$44.30M |
| YoY Change | -54.84% | -40.78% |
| Income Tax | $0.00 | |
| % Of Pretax Income | ||
| Net Earnings | -$20.00M | -$44.30M |
| YoY Change | -54.84% | -40.76% |
| Net Earnings / Revenue | -53.92% | |
| Basic Earnings Per Share | -$0.29 | |
| Diluted Earnings Per Share | -$0.29 | -$737.1K |
| COMMON SHARES | ||
| Basic Shares Outstanding | 69.14M | |
| Diluted Shares Outstanding | 69.14M |
Balance Sheet
| Concept | 2019 Q1 | 2018 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $96.40M | $95.20M |
| YoY Change | 1.26% | -45.54% |
| Cash & Equivalents | $81.52M | $82.02M |
| Short-Term Investments | $14.90M | $13.10M |
| Other Short-Term Assets | $14.00M | $17.10M |
| YoY Change | -18.13% | -48.8% |
| Inventory | $2.312M | |
| Prepaid Expenses | ||
| Receivables | $46.50M | |
| Other Receivables | $0.00 | |
| Total Short-Term Assets | $159.2M | $112.2M |
| YoY Change | 41.89% | -46.14% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $12.90M | $11.90M |
| YoY Change | 8.4% | -20.13% |
| Goodwill | $943.0K | |
| YoY Change | ||
| Intangibles | $2.620M | |
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $14.00K | $800.0K |
| YoY Change | -98.25% | 0.0% |
| Total Long-Term Assets | $26.92M | $16.30M |
| YoY Change | 65.12% | -15.1% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $159.2M | $112.2M |
| Total Long-Term Assets | $26.92M | $16.30M |
| Total Assets | $186.1M | $128.5M |
| YoY Change | 44.84% | -43.52% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $11.17M | $14.30M |
| YoY Change | -21.87% | 13.49% |
| Accrued Expenses | $8.857M | $9.400M |
| YoY Change | -5.78% | -58.77% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $41.40M | $27.62M |
| YoY Change | 49.87% | -41.6% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $176.6M | $102.0M |
| YoY Change | 73.14% | 1.39% |
| Other Long-Term Liabilities | $1.960M | |
| YoY Change | -27.41% | |
| Total Long-Term Liabilities | $0.00 | $1.960M |
| YoY Change | -100.0% | -98.1% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $41.40M | $27.62M |
| Total Long-Term Liabilities | $0.00 | $1.960M |
| Total Liabilities | $224.6M | $131.6M |
| YoY Change | 70.76% | -11.89% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$1.005B | |
| YoY Change | ||
| Common Stock | $966.7M | $818.8M |
| YoY Change | 18.07% | |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | -$38.50M | -$1.800M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $186.1M | $128.5M |
| YoY Change | 44.88% | -43.53% |
Cashflow Statement
| Concept | 2019 Q1 | 2018 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$20.00M | -$44.30M |
| YoY Change | -54.84% | -40.76% |
| Depreciation, Depletion And Amortization | $700.0K | $900.0K |
| YoY Change | -22.22% | 0.0% |
| Cash From Operating Activities | -$56.98M | -$33.58M |
| YoY Change | 69.67% | -54.18% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $335.0K | $81.00K |
| YoY Change | 313.58% | -95.21% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | -$14.90M | -$13.10M |
| YoY Change | 13.74% | -73.75% |
| Cash From Investing Activities | -$15.20M | -$13.18M |
| YoY Change | 15.31% | -74.46% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 81.48M | 1.878M |
| YoY Change | 4238.5% | -98.5% |
| NET CHANGE | ||
| Cash From Operating Activities | -56.98M | -33.58M |
| Cash From Investing Activities | -15.20M | -13.18M |
| Cash From Financing Activities | 81.48M | 1.878M |
| Net Change In Cash | 9.159M | -44.90M |
| YoY Change | -120.4% | 195117.39% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$56.98M | -$33.58M |
| Capital Expenditures | $335.0K | $81.00K |
| Free Cash Flow | -$57.32M | -$33.67M |
| YoY Change | 70.26% | -55.11% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2018Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
33261000 | |
| CY2019Q1 | us-gaap |
Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
|
77614000 | |
| CY2018Q4 | us-gaap |
Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
|
77319000 | |
| CY2019Q1 | us-gaap |
Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
|
25872000 | |
| CY2018Q4 | us-gaap |
Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
|
25773000 | |
| CY2019Q1 | us-gaap |
Long Term Debt
LongTermDebt
|
73124000 | |
| CY2018Q4 | us-gaap |
Long Term Debt
LongTermDebt
|
||
| CY2018Q4 | chrs |
Accrued Rebates Fees And Reserve Current
AccruedRebatesFeesAndReserveCurrent
|
||
| CY2019Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
7292000 | |
| CY2018Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
10540000 | |
| CY2019Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
8857000 | |
| CY2018Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
7008000 | |
| CY2018Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
419000 | |
| CY2019Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
6549000 | |
| CY2018Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
||
| CY2019Q1 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
||
| CY2018Q4 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
||
| CY2019Q1 | us-gaap |
Receivables Net Current
ReceivablesNetCurrent
|
46476000 | |
| CY2018Q4 | us-gaap |
Receivables Net Current
ReceivablesNetCurrent
|
||
| CY2019Q1 | us-gaap |
Inventory Net
InventoryNet
|
2312000 | |
| CY2018Q4 | us-gaap |
Inventory Net
InventoryNet
|
1659000 | |
| CY2019Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
5638000 | |
| CY2018Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2462000 | |
| CY2019Q1 | us-gaap |
Inventory Noncurrent
InventoryNoncurrent
|
9700000 | |
| CY2018Q4 | us-gaap |
Inventory Noncurrent
InventoryNoncurrent
|
4012000 | |
| CY2019Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
6766000 | |
| CY2018Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
||
| CY2018Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
2620000 | |
| CY2018Q4 | us-gaap |
Goodwill
Goodwill
|
943000 | |
| CY2018Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
785000 | |
| CY2018Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
14000 | |
| CY2019Q1 | us-gaap |
Assets
Assets
|
186115000 | |
| CY2018Q4 | us-gaap |
Assets
Assets
|
99467000 | |
| CY2018Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
15294000 | |
| CY2019Q1 | chrs |
Accrued Rebates Fees And Reserve Current
AccruedRebatesFeesAndReserveCurrent
|
11945000 | |
| CY2019Q1 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | |
| CY2019Q2 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
69370457 | |
| CY2019Q1 | dei |
Entity Small Business
EntitySmallBusiness
|
false | |
| CY2018Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
72356000 | |
| CY2019Q1 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
14918000 | |
| CY2019Q1 | chrs |
Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
|
8249000 | |
| CY2018Q4 | chrs |
Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
|
7906000 | |
| CY2019Q1 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
2620000 | |
| CY2019Q1 | us-gaap |
Goodwill
Goodwill
|
943000 | |
| CY2019Q1 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
785000 | |
| CY2019Q1 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
14000 | |
| CY2019Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
11173000 | |
| CY2018Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-42032000 | |
| CY2018Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
42032000 | |
| CY2019Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-20140000 | |
| CY2018Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
1645000 | |
| CY2019Q1 | us-gaap |
Liabilities
Liabilities
|
224630000 | |
| CY2018Q4 | us-gaap |
Liabilities
Liabilities
|
138058000 | |
| CY2019Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2018Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2019Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2018Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2019Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
7000 | |
| CY2018Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
7000 | |
| CY2019Q1 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
966731000 | |
| CY2018Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
946515000 | |
| CY2019Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-418000 | |
| CY2018Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-282000 | |
| CY2019Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-1004835000 | |
| CY2018Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-984831000 | |
| CY2019Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
-38515000 | |
| CY2018Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
-38591000 | |
| CY2019Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
186115000 | |
| CY2018Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
99467000 | |
| CY2019Q1 | us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
37098000 | |
| CY2018Q1 | us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
0 | |
| CY2019Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
2225000 | |
| CY2018Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
0 | |
| CY2019Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
32683000 | |
| CY2018Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
16577000 | |
| CY2018Q1 | us-gaap |
Interest Expense
InterestExpense
|
2408000 | |
| CY2018Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
138000 | |
| CY2018Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-44302000 | |
| CY2018Q1 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-5000 | |
| CY2018Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-44297000 | |
| CY2018Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.74 | |
| CY2018Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
60122050 | |
| CY2018Q1 | us-gaap |
Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
|
34000 | |
| CY2018Q1 | us-gaap |
Interest Expense Related Party
InterestExpenseRelatedParty
|
602000 | |
| CY2019Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
0 | |
| CY2018Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-1000 | |
| CY2019Q1 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-136000 | |
| CY2018Q1 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-13000 | |
| CY2019Q1 | us-gaap |
Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
|
-20140000 | |
| CY2018Q1 | us-gaap |
Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
|
-44316000 | |
| CY2019Q1 | us-gaap |
Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
|
0 | |
| CY2018Q1 | us-gaap |
Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
|
-5000 | |
| CY2018Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-44311000 | |
| CY2019Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
825000 | |
| CY2019Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
9813000 | |
| CY2017Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
30535000 | |
| CY2018Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
44000 | |
| CY2019Q1 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
547000 | |
| CY2018Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
225000 | |
| CY2018Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
8720000 | |
| CY2018Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
-3088000 | |
| CY2019Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
691000 | |
| CY2018Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
922000 | |
| CY2019Q1 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
4000 | |
| CY2018Q1 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
208000 | |
| CY2019Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
54000 | |
| CY2018Q1 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
358000 | |
| CY2019Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
9494000 | |
| CY2018Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
8720000 | |
| CY2019Q1 | chrs |
Excess And Obsolete Inventory
ExcessAndObsoleteInventory
|
410000 | |
| CY2018Q1 | chrs |
Excess And Obsolete Inventory
ExcessAndObsoleteInventory
|
0 | |
| CY2019Q1 | chrs |
Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
|
405000 | |
| CY2018Q1 | chrs |
Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
|
0 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Receivables
IncreaseDecreaseInReceivables
|
46476000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Receivables
IncreaseDecreaseInReceivables
|
0 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
6432000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
0 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
343000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
-763000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
2799000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-715000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-3964000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-1068000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
|
0 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
|
-199000 | |
| CY2019Q1 | chrs |
Increase Decrease In Accrued Rebates Fees And Returns
IncreaseDecreaseInAccruedRebatesFeesAndReturns
|
11945000 | |
| CY2018Q1 | chrs |
Increase Decrease In Accrued Rebates Fees And Returns
IncreaseDecreaseInAccruedRebatesFeesAndReturns
|
0 | |
| CY2019Q1 | chrs |
Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
|
-1898000 | |
| CY2018Q1 | chrs |
Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
|
1953000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
2027000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
-1497000 | |
| CY2019Q1 | chrs |
Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
|
-506000 | |
| CY2018Q1 | chrs |
Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
|
0 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
-30000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
-113000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-56983000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-33584000 | |
| CY2019Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
335000 | |
| CY2018Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
81000 | |
| CY2019Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
14864000 | |
| CY2018Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
13100000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-15199000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-13181000 | |
| CY2019Q1 | chrs |
Proceeds From Issuance Common Stock Offering Net Of Underwriters Discounts Commissions And Offering Costs
ProceedsFromIssuanceCommonStockOfferingNetOfUnderwritersDiscountsCommissionsAndOfferingCosts
|
8153000 | |
| CY2018Q1 | chrs |
Proceeds From Issuance Common Stock Offering Net Of Underwriters Discounts Commissions And Offering Costs
ProceedsFromIssuanceCommonStockOfferingNetOfUnderwritersDiscountsCommissionsAndOfferingCosts
|
1653000 | |
| CY2019Q1 | us-gaap |
Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
|
72876000 | |
| CY2018Q1 | us-gaap |
Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
|
0 | |
| CY2019Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
448000 | |
| CY2018Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
225000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
81477000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
1878000 | |
| CY2019Q1 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
-136000 | |
| CY2018Q1 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
-13000 | |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
9159000 | |
| CY2018Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-44900000 | |
| CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
73191000 | |
| CY2017Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
127756000 | |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
82350000 | |
| CY2018Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
82856000 | |
| CY2019Q1 | chrs |
Non Cash Bonus Payment Settled In Common Stock
NonCashBonusPaymentSettledInCommonStock
|
1350000 | |
| CY2018Q1 | chrs |
Non Cash Bonus Payment Settled In Common Stock
NonCashBonusPaymentSettledInCommonStock
|
0 | |
| CY2019Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Organization and Operations<font style="font-weight:normal;"> </font></p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Description of the Business </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Coherus BioSciences, Inc. (the “Company”, “Coherus”, “we”, our” or “us”) is a commercial-stage biotherapeutics company, focused on the global biosimilar market. The Company’s headquarters and laboratories are located in Redwood City, California and in Camarillo, California, respectively. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 25, 2018, the Company received regulatory approval for the marketing of UDENYCA<sup style="font-size:85%; vertical-align:top">®</sup> (pegfilgrastim-cbqv), a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor, from the European Commission, and received regulatory approval for UDENYCA<sup style="font-size:85%; vertical-align:top">®</sup> from the U.S. Food and Drug Administration (“FDA”) on November 2, 2018. The Company initiated U.S. sales of UDENYCA<sup style="font-size:85%; vertical-align:top">®</sup> on January 3, 2019.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Need to Raise Additional Capital<font style="font-weight:normal;"> </font></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2019, the Company had an accumulated deficit of $1.0 billion and cash and cash equivalents and short-term investments in marketable securities of $96.4 million. In January 2019, the Company issued and sold 761,130 shares of common stock at a weighted average price of $11.17 per share through its ATM Offering Program and received total net proceeds of $8.2 million (see Note 10). As of January 19, 2019, the Company’s Shelf Registration Statement expired and accordingly the ATM Program was terminated. <font style="color:#000000;">The Company also entered into a credit agreement (the “Term Loan”) with affiliates of Healthcare Royalty Partners consisting of a six-year term loan facility for an aggregate principal of $75.0 million in January 2019.</font> The Company believes that its current available cash, cash equivalents, short-term investments in marketable securities and cash collected from <font style="color:#000000;">UDENYCA<sup style="font-size:85%; vertical-align:top">®</sup> sales </font>will be sufficient to fund its planned expenditures and meet the Company’s obligations <font style="color:#000000;">for at least 12 months following our financial statement issuance date</font><font style="color:#1F497D;">. </font>The Company may need to raise additional funds in the future; however, there can be no assurance that such efforts will be successful or that, in the event that they are successful, the terms and conditions of such financing will be favorable. If the Company is unable to generate sufficient cash from product sales or to obtain adequate financing when needed, it may have to delay, reduce the scope of or suspend one or more of its clinical trials, research and development programs or commercialization efforts.</p> | |
| CY2019Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make judgements, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue and expenses, and related disclosures. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates. </p> | |
| CY2018Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
82021000 | |
| CY2018Q1 | us-gaap |
Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
|
50000 | |
| CY2018Q1 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
785000 | |
| CY2019Q1 | chrs |
Write Off Of Prepaid Manufacturing Costs
WriteOffOfPrepaidManufacturingCosts
|
1300000 | |
| CY2019Q1 | us-gaap |
Inventory Write Down
InventoryWriteDown
|
400000 | |
| CY2019Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
22270300 | |
| CY2018Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
18379251 | |
| CY2019Q1 | us-gaap |
Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
|
0 | |
| CY2019Q1 | us-gaap |
Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
|
0 | |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
96400000 | |
| CY2019Q1 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-169000 | |
| CY2018Q1 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
8000 | |
| CY2019Q1 | us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
1 | |
| CY2019Q1 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
| CY2018Q4 | us-gaap |
Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
|
0 | |
| CY2019Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
7200000 | |
| CY2019Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
9200000 | |
| CY2019Q1 | us-gaap |
Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Into Level3
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersIntoLevel3
|
0 | |
| CY2018 | us-gaap |
Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Into Level3
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersIntoLevel3
|
0 | |
| CY2019Q1 | us-gaap |
Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Out Of Level3
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3
|
0 | |
| CY2018 | us-gaap |
Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Out Of Level3
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3
|
0 | |
| CY2019Q1 | us-gaap |
Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
|
112000 | |
| CY2018Q1 | us-gaap |
Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
|
82000 | |
| CY2019Q1 | us-gaap |
Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
|
0 | |
| CY2018Q1 | us-gaap |
Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
|
0 | |
| CY2019Q1 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
2094000 | |
| CY2018Q4 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
2851000 | |
| CY2019Q1 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
6484000 | |
| CY2018Q4 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
1576000 | |
| CY2019Q1 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
3434000 | |
| CY2018Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
1244000 | |
| CY2019Q1 | us-gaap |
Inventory Gross
InventoryGross
|
12012000 | |
| CY2018Q4 | us-gaap |
Inventory Gross
InventoryGross
|
5671000 | |
| CY2019Q1 | chrs |
Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
|
12012000 | |
| CY2018Q4 | chrs |
Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
|
5671000 | |
| CY2019Q1 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
19857000 | |
| CY2018Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
19697000 | |
| CY2019Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
13728000 | |
| CY2018Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
13037000 | |
| CY2019Q1 | chrs |
Accrued Clinical And Manufacturing Liabilities Current
AccruedClinicalAndManufacturingLiabilitiesCurrent
|
4267000 | |
| CY2018Q4 | chrs |
Accrued Clinical And Manufacturing Liabilities Current
AccruedClinicalAndManufacturingLiabilitiesCurrent
|
3950000 | |
| CY2019Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
4590000 | |
| CY2018Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
3058000 | |
| CY2018Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
0 | |
| CY2019Q1 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
30724000 | |
| CY2019Q1 | chrs |
Allowance For Doubtful Accounts Receivable Payments And Customer Credits Issued
AllowanceForDoubtfulAccountsReceivablePaymentsAndCustomerCreditsIssued
|
3024000 | |
| CY2019Q1 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
27700000 | |
| CY2019Q1 | us-gaap |
Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
|
133600000 | |
| CY2019Q1 | us-gaap |
Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
|
4385000 | |
| CY2019Q1 | us-gaap |
Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
|
24975000 | |
| CY2019Q1 | us-gaap |
Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
|
600000 | |
| CY2019Q1 | us-gaap |
Purchase Obligation Due In Fourth Year
PurchaseObligationDueInFourthYear
|
600000 | |
| CY2019Q1 | us-gaap |
Purchase Obligation
PurchaseObligation
|
30560000 | |
| CY2015Q3 | us-gaap |
Area Of Real Estate Property
AreaOfRealEstateProperty
|
40341 | |
| CY2019Q1 | chrs |
Number Of Laboratory Facility Structure
NumberOfLaboratoryFacilityStructure
|
2 | |
| CY2019Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
2140000 | |
| CY2019Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
8689000 | |
| CY2019Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
500000 | |
| CY2019Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
700000 | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
1996000 | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
2695000 | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
2672000 | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
2518000 | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
9881000 | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
1192000 | |
| CY2019Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P3Y7M6D | |
| CY2019Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.070 |
